ResMed (ASX:RMD) is the leading business in the treatment of sleep apnea. 2018 has seen the stock price up over 40% from $10.78 to $16.23, but is there still room to grow?
The business is centered in the US, however they have opportunities to expand into the enormous Chinese market. ResMed have also expanded into the digital health market via acquisitions and have now partnered with Google’s healthcare arm, Verily.
The share price does seem on the expensive side, however, with the company’s focus on long term investments designed for growth, this stock should continue to see investors gaining healthy returns in the long run.
Please follow and like us: